Hills Bank Trust Co Lowers stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Hills Bank Trust Co reduced its stake in Johnson & Johnson by 3.8% during the most recent quarter end. The investment management company now holds a total of 43,978 shares of Johnson & Johnson which is valued at $4,929,054 after selling 1,735 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Apr 25, 2016.Johnson & Johnson makes up approximately 1.81% of Hills Bank Trust Co’s portfolio.

Johnson & Johnson opened for trading at $112.22 and hit $112.7897 on the upside on Monday, eventually ending the session at $112.75, with a gain of 0.60% or 0.67 points. The heightened volatility saw the trading volume jump to 51,78,847 shares. Company has a market cap of $311,118 M.

Other Hedge Funds, Including , North Star Investment Management Corp. reduced its stake in JNJ by selling 1,692 shares or 1.99% in the most recent quarter. The Hedge Fund company now holds 83,185 shares of JNJ which is valued at $9,323,375. Johnson & Johnson makes up approx 1.77% of North Star Investment Management Corp.’s portfolio.First Manhattan Co reduced its stake in JNJ by selling 119,024 shares or 4.21% in the most recent quarter. The Hedge Fund company now holds 2,705,568 shares of JNJ which is valued at $306,594,966. Johnson & Johnson makes up approx 1.86% of First Manhattan Co’s portfolio.Concannon Wealth Management reduced its stake in JNJ by selling 445 shares or 15.85% in the most recent quarter. The Hedge Fund company now holds 2,363 shares of JNJ which is valued at $267,775. Johnson & Johnson makes up approx 0.27% of Concannon Wealth Management’s portfolio.Blue Fin Capital reduced its stake in JNJ by selling 1,965 shares or 9.19% in the most recent quarter. The Hedge Fund company now holds 19,413 shares of JNJ which is valued at $2,138,924. Johnson & Johnson makes up approx 1.80% of Blue Fin Capital’s portfolio.

On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.